Aevisbio provides a scientific solution for the innovative drug development targeting incurable diseases such as inflammatory diseases, neurological disorders and drug resistant cancers.
Aevisbio has identified a novel series of Immunomodulatory imide drugs (IMiDs), exhibit multiple biological effects providing diverse drug development platforms such as TArgeted Proteolysis Inducer (TAPI).
